These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 1727368

  • 1. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
    Hornung RL, Pearson JW, Beckwith M, Longo DL.
    Cancer Res; 1992 Jan 01; 52(1):101-7. PubMed ID: 1727368
    [Abstract] [Full Text] [Related]

  • 2. Successful treatment of murine melanoma with bryostatin 1.
    Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD.
    Cancer Res; 1991 Jan 15; 51(2):682-7. PubMed ID: 1985785
    [Abstract] [Full Text] [Related]

  • 3. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
    Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM.
    Cancer Res; 1996 May 01; 56(9):2105-11. PubMed ID: 8616857
    [Abstract] [Full Text] [Related]

  • 4. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD.
    Cancer Res; 1992 Feb 01; 52(3):548-53. PubMed ID: 1732041
    [Abstract] [Full Text] [Related]

  • 5. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM.
    Clin Cancer Res; 2000 Dec 01; 6(12):4950-6. PubMed ID: 11156256
    [Abstract] [Full Text] [Related]

  • 6. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
    Berkow RL, Schlabach L, Dodson R, Benjamin WH, Pettit GR, Rustagi P, Kraft AS.
    Cancer Res; 1993 Jun 15; 53(12):2810-5. PubMed ID: 8504423
    [Abstract] [Full Text] [Related]

  • 7. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK.
    Clin Cancer Res; 2000 Apr 15; 6(4):1498-507. PubMed ID: 10778982
    [Abstract] [Full Text] [Related]

  • 8. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.
    Kraft AS, Adler V, Hall P, Pettit GR, Benjamin WH, Briles DE.
    Cancer Res; 1992 Apr 15; 52(8):2143-7. PubMed ID: 1559218
    [Abstract] [Full Text] [Related]

  • 9. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 10. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A.
    Clin Cancer Res; 1998 May 15; 4(5):1337-43. PubMed ID: 9607595
    [Abstract] [Full Text] [Related]

  • 11. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
    Tsuruo T, Yusa K, Sudo Y, Takamori R, Sugimoto Y.
    Cancer Res; 1989 Oct 15; 49(20):5537-42. PubMed ID: 2790778
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH.
    Cancer Res; 1990 Sep 01; 50(17):5414-20. PubMed ID: 2117482
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J.
    Cancer Res; 1987 Jul 15; 47(14):3707-11. PubMed ID: 3594435
    [Abstract] [Full Text] [Related]

  • 14. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL, Roberts BJ, Howard CT, Leopold WR.
    Cancer Res; 1994 Aug 15; 54(16):4412-8. PubMed ID: 8044790
    [Abstract] [Full Text] [Related]

  • 15. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.
    Bousquet PF, Paulsen LA, Fondy C, Lipski KM, Loucy KJ, Fondy TP.
    Cancer Res; 1990 Mar 01; 50(5):1431-9. PubMed ID: 2302708
    [Abstract] [Full Text] [Related]

  • 16. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
    Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD.
    Int Immunol; 2004 Sep 01; 16(9):1283-94. PubMed ID: 15262898
    [Abstract] [Full Text] [Related]

  • 17. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM.
    Clin Cancer Res; 1998 Feb 01; 4(2):445-53. PubMed ID: 9516935
    [Abstract] [Full Text] [Related]

  • 18. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.
    Pierré A, Kraus-Berthier L, Atassi G, Cros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP.
    Cancer Res; 1991 May 01; 51(9):2312-8. PubMed ID: 2015595
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS, Clement JJ.
    Cancer Res; 1989 Jun 01; 49(11):2935-40. PubMed ID: 2720652
    [Abstract] [Full Text] [Related]

  • 20. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
    Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, Tsuruo T.
    Oncol Res; 1997 Jun 01; 9(2):61-9. PubMed ID: 9167187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.